Bausch Health to Announce First Quarter 2026 Results on April 29, 2026
Bausch Health (NYSE:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026.
Rhea-AI Summary
Bausch Health (NYSE:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026.
The company will host a live conference call and webcast at 5:00 p.m. U.S. EDT the same day; materials and a replay will be available on the Investor Relations website prior to and after the call.
Positive
- None.
Negative
- None.
Details
News Market Reaction – BHC
On Mar 31, the day this news came out, BHC closed 7.36% above the previous close.
Data tracked by StockTitan Argus for the Mar 31 session.
Key Figures
- Q1 2026 release date
- April 29, 2026
- Scheduled earnings release after market close
- Earnings call time
- 5:00 p.m. U.S. EDT
- Q1 2026 conference call and webcast
- Q4 2025 revenue
- $2.80 billion
- Q4 2025 consolidated revenues, +9% reported, +6% organic
- FY 2025 revenue
- $10.27 billion
- Full‑year 2025 consolidated revenues, +7% reported, +5% organic
- Q4 2025 GAAP net loss
- $112 million
- Q4 2025 GAAP net loss
- FY 2025 GAAP net income
- $157 million
- Full‑year 2025 GAAP net income
- FY 2026 revenue guide
- $10.625–$10.875 billion
- 2026 revenue guidance provided on Feb 18, 2026
- FY 2026 EBITDA guide
- $3.875–$4.000 billion
- 2026 adjusted EBITDA guidance from Q4 2025 release
Previous Earnings date Reports
-
Announced timing of Q4 and full‑year 2025 results and investor call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Details
Date: Wednesday, April 29, 2026
Time: 5:00 p.m.
Webcast: http://ir.bauschhealth.com/events-and-presentations
A replay of the conference call will be available on the investor relations website.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on LinkedIn.
Investor Contact: | Media Contact: | |
Garen Sarafian | Katie Savastano | |
(877) 281-6642 (toll-free) | (908) 541-3785 | |
BHC-FINANCIAL |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-health-to-announce-first-quarter-2026-results-on-april-29-2026-302728610.html
SOURCE Bausch Health Companies Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
